Lorlatinib shows promising results in clinical trials with patients suffering from non-small-cell lung cancer with genetic rearrangement of ALK or ROS124,25, however, only a very small percentage of human PDAC patients have detectable ALK expression37. The gene discussed is ALK; the disease is non-small cell lung carcinoma.